uniQure BV (QURE) Sell-Off 'Unfounded' - Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St futures muted as investors monitor US-Iran negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Chardan Capital Says uniQure (QURE) on Pullback, Slight Delay to AMT-060 is Immaterial
December 1, 2015 10:04 AM ESTChardan Capital affirms its Buy rating and $40 price target on uniQure N.V. (Nasdaq: QURE) following the company's Q3 report and update issued on Monday.
Analyst Gbola Amusa says investors should buy on post-Q3 weakness. The analyst noted the following key points from the company's quarterly conference call:
AMT-060 (hemophilia B): In early January 2016 (previously due by end-2015), uniQure will release preliminary, top-line data for 2 patients who have completed at least 12 weeks of treatment, with full results from the first cohort of 5 patients at a scientific conference... MoreuniQure (QURE) Ests and PT Cut After Dropping Glybera - Jefferies
December 1, 2015 9:49 AM ESTJefferies analyst, Eun Yang, reduced the price target on uniQure BV (NASDAQ: QURE) to $36 vs $40 previously. The drop takes into account the loss of revenue from the removal of Glybera and increasing the discount rate to 13% (from 12%) to reflect yet-to-be proven commercial potential/success of gene therapy products. No change to... More
Janney Capital Starts uniQure BV (QURE) at Buy
November 30, 2015 5:10 PM ESTJanney Capital initiated coverage on uniQure BV (NASDAQ: QURE) with a Buy rating and a price target of $40.00.
For an analyst ratings summary and ratings history on uniQure BV click here. For more ratings news on uniQure BV click here.
Shares of uniQure BV closed at $22.50 yesterday.
... MoreuniQure BV (QURE) Ph1/2 MPS3b Has Strong Reception at ICSS - Cowen
November 30, 2015 7:44 AM ESTCowen analyst Ritu Baral reiterated an Outperform rating on uniQure BV (NASDAQ: QURE) Ph1/2 12 mo. MPS3b AMT-110 data was presented again at ICSS Friday and was very well received by MPS3 KOLs.
Baral commented, "The trial PI noted 18 more mos. of... More
uniQure (QURE) Misses Q3 EPS by 3c
November 30, 2015 7:34 AM ESTuniQure (NASDAQ: QURE) reported Q3 EPS of (EUR0.67), EUR0.03 worse than the analyst estimate of (EUR0.64). Revenue for the quarter came in at EUR3.15 million versus the consensus estimate of EUR2.8 million.
For earnings history and earnings-related data on uniQure (QURE) click here.
... More